Physician profile
Farida Migally
NPI 1730474776
$29,551.33
in general payments reported to CMS, 2019-2025
15 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $1,076 · 2021: $7,296 · 2022: $6,595 · 2023: $14K · 2024: $234 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $1,107 · Travel and Lodging: $520 · Education: $29.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,650.00 |
| Food and Beverage | $1,107.42 |
| Travel and Lodging | $520.39 |
| Education | $29.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27,619.65 | 2019-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $1,019.94 | 2020-2023 | Velphoro |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Bard Peripheral Vascular, INC. | $139.73 | 2019 | |
| Lilly USA, LLC | $132.95 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $109.63 | 2022-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.18 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $54.41 | 2024-2025 | |
| Lemaitre Vascular, INC. | $51.83 | 2022-2025 | Artegraft Vascular Graft |
| Akebia Therapeutics INC | $49.99 | 2020-2025 | Vafseo |
| Travere Therapeutics, INC. | $44.63 | 2024 | |
| Ardelyx, INC. | $16.86 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $14.13 | 2025 | |
| Amgen INC. | $13.70 | 2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $13.70 | 2025 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farida Migally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.